Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical company POZEN
With that in mind, let's take a closer look at POZEN's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Chapel Hill, N.C. (1996)|
|Market Cap||$200.4 million|
|Trailing-12-Month Revenue||$83.8 million|
|Management||Co-Founder/Chairman/CEO Dr. John Plachetka
CFO William Hodges
|Return on Equity (average, past 3 years)||26.3%|
|Cash/Debt||$100.8 million / $0|
Endo Health Solutions
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 14% of the 222 members who have rated POZEN believe the stock will underperform the S&P 500 going forward.
Pozen seems to have a neverending supply of optimistic investors who think that the next drug they get approved will be a commercial success. First Treximet and then Vimovo proved to be predictable failures, and I don't see any reason why PA32540 won't follow the same path. There may still some good times with FDA approval and bullish remarks from sell-side analysts, but ultimately I think we're looking at a retracement of the lows.
If you want market-thumping returns, you need to protect your portfolio from any undue risk. Luckily, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap growth play with big potential. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.